VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 04, 2019 08:00 ET | VBI Vaccines, Inc.
  Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
Logo new.jpg
Vivos Inc. Reports on the Health of Canine Therapy Patients
February 25, 2019 07:00 ET | Vivos Inc.
Richland WA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive...